Mineralys Therapeutics, Inc.
MLYS
$14.25
$0.755.56%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 17.60% | 3.83% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -13.87% | 33.07% | |||
| Operating Income | 13.87% | -33.07% | |||
| Income Before Tax | 13.13% | -37.37% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 13.13% | -37.37% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 13.13% | -37.37% | |||
| EBIT | 13.87% | -33.07% | |||
| EBITDA | 13.88% | -33.07% | |||
| EPS Basic | 13.40% | -36.10% | |||
| Normalized Basic EPS | 13.40% | -36.10% | |||
| EPS Diluted | 13.40% | -36.10% | |||
| Normalized Diluted EPS | 13.40% | -36.10% | |||
| Average Basic Shares Outstanding | 0.31% | 0.93% | |||
| Average Diluted Shares Outstanding | 0.31% | 0.93% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
